BidaskClub downgraded shares of Aduro BioTech (NASDAQ:ADRO) from a strong-buy rating to a buy rating in a research report report published on Friday, April 6th.
Several other research analysts have also commented on the stock. ValuEngine lowered shares of Aduro BioTech from a sell rating to a strong sell rating in a research note on Friday, April 6th. Zacks Investment Research cut shares of Aduro BioTech from a buy rating to a hold rating in a report on Wednesday, March 7th. Cantor Fitzgerald reaffirmed a buy rating and issued a $15.00 target price on shares of Aduro BioTech in a report on Monday, March 5th. Bank of America reduced their target price on shares of Aduro BioTech from $9.00 to $8.00 and set an underperform rating on the stock in a report on Friday, March 2nd. Finally, Canaccord Genuity reaffirmed a buy rating on shares of Aduro BioTech in a report on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $14.50.
NASDAQ ADRO opened at $7.20 on Friday. Aduro BioTech has a one year low of $5.82 and a one year high of $14.05. The company has a market capitalization of $611.60, a PE ratio of -5.07 and a beta of 2.07.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.35) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%. The business had revenue of $3.76 million during the quarter, compared to analyst estimates of $4.32 million. sell-side analysts expect that Aduro BioTech will post -1.29 EPS for the current year.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 72,051 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $8.48, for a total transaction of $610,992.48. Following the sale, the insider now owns 231,380 shares of the company’s stock, valued at $1,962,102.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $8.91, for a total transaction of $356,400.00. Following the sale, the insider now directly owns 245,746 shares in the company, valued at approximately $2,189,596.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 118,925 shares of company stock worth $1,011,936. 6.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in ADRO. Bank of New York Mellon Corp raised its holdings in Aduro BioTech by 23.9% during the third quarter. Bank of New York Mellon Corp now owns 175,642 shares of the biotechnology company’s stock worth $1,871,000 after purchasing an additional 33,843 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Aduro BioTech in the 3rd quarter valued at $167,000. Trexquant Investment LP acquired a new position in shares of Aduro BioTech in the 3rd quarter valued at $175,000. Wells Fargo & Company MN increased its holdings in shares of Aduro BioTech by 111.5% in the 3rd quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 38,415 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Aduro BioTech by 5.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock valued at $1,859,000 after acquiring an additional 9,140 shares during the period. 44.94% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2018/04/15/aduro-biotech-adro-stock-rating-lowered-by-bidaskclub.html.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.